BioWorld

Jan. 16, 2004

Genentech Beats 4Q Estimates, Files To Expand Nutropin Label

Genentech Inc. released year-end and quarterly earnings that beat consensus estimates, simultaneously disclosing its application for an expanded indication of one of its growth hormone products. (BioWorld Today) Read More

JPMorgan, Bank One Merger Puts 'Uncertainty' On Biotech

TargeGen's Series B Brings In $30M For AMI, Cancer Programs

NovaScreen Signs Biodefense Contract On Immune Boosters

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 10, 2025.

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Red blood cells in an artery with cholesterol

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

BioWorld

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...

Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...